Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).
Hernández-Bernal F, Ricardo-Cobas MC, Martín-Bauta Y, Navarro-Rodríguez Z, Piñera-Martínez M, Quintana-Guerra J, Urrutia-Pérez K, Urrutia-Pérez K, Chávez-Chong CO, Azor-Hernández JL, Rodríguez-Reinoso JL, Lobaina-Lambert L, Colina-Ávila E, Bizet-Almeida J, Rodríguez-Nuviola J, Del Valle-Piñera S, Ramírez-Domínguez M, Tablada-Ferreiro E, Alonso-Valdés M, Lemos-Pérez G, Guillén-Nieto GE, Palenzuela-Díaz A, Noa-Romero E, Limonta-Fernández M, Fernández-Ávila JM, Ali-Mros NA, Del Toro-Lahera L, Remedios-Reyes R, Ayala-Ávila M, Muzio-González VL. Hernández-Bernal F, et al. Among authors: ayala avila m. EClinicalMedicine. 2022 Apr;46:101383. doi: 10.1016/j.eclinm.2022.101383. Epub 2022 Apr 9. EClinicalMedicine. 2022. PMID: 35434578 Free PMC article.
An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen.
Limonta-Fernández M, Chinea-Santiago G, Martín-Dunn AM, Gonzalez-Roche D, Bequet-Romero M, Marquez-Perera G, González-Moya I, Canaan-Haden-Ayala C, Cabrales-Rico A, Espinosa-Rodríguez LA, Ramos-Gómez Y, Andujar-Martínez I, González-López LJ, de la Iglesia MP, Zamora-Sanchez J, Cruz-Sui O, Lemos-Pérez G, Cabrera-Herrera G, Valdes-Hernández J, Martinez-Diaz E, Pimentel-Vazquez E, Ayala-Avila M, Guillén-Nieto G. Limonta-Fernández M, et al. Among authors: ayala avila m. N Biotechnol. 2022 Dec 25;72:11-21. doi: 10.1016/j.nbt.2022.08.002. Epub 2022 Aug 8. N Biotechnol. 2022. PMID: 35953030 Free PMC article.
Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study.
Más-Bermejo PI, Dickinson-Meneses FO, Almenares-Rodríguez K, Sánchez-Valdés L, Guinovart-Díaz R, Vidal-Ledo M, Galbán-García E, Olivera-Nodarse Y, Morgado-Vega I, Dueñas-Carrera S, Pujol M, Hernández-Bernal F, Limonta-Fernández M, Guillén-Nieto G, Muzio-González VL, Ayala-Ávila M. Más-Bermejo PI, et al. Among authors: ayala avila m. Lancet Reg Health Am. 2022 Dec;16:100366. doi: 10.1016/j.lana.2022.100366. Epub 2022 Sep 24. Lancet Reg Health Am. 2022. PMID: 36185968 Free PMC article.
Correction to "Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study" [The Lancet Regional Health - Americas 2022; 16: 100366] https://doi.org/10.1016/j.lana.2022.100366.
Más-Bermejo PI, Dickinson-Meneses FO, Almenares-Rodríguez K, Sánchez-Valdés L, Guinovart-Díaz R, Vidal-Ledo M, Galbán-García E, Olivera-Nodarse Y, Morgado-Vega I, Dueñas-Carrera S, Pujol M, Hernández-Bernal F, Limonta-Fernández M, Guillén-Nieto G, Muzio-González VL, Ayala-Ávila M. Más-Bermejo PI, et al. Among authors: ayala avila m. Lancet Reg Health Am. 2023 Feb;18:100422. doi: 10.1016/j.lana.2022.100422. Epub 2022 Dec 29. Lancet Reg Health Am. 2023. PMID: 36593764 Free PMC article.
Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3-18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study).
Cinza-Estévez Z, Resik-Aguirre S, Figueroa-Baile NL, Oquendo-Martínez R, Campa-Legrá I, Tejeda-Fuentes A, Rivero-Caballero M, González-García G, Chávez-Chong CO, Alonso-Valdés M, Hernández-Bernal F, Lemos-Pérez G, Campal-Espinosa A, Freyre-Corrales G, Benítez-Gordillo D, Gato-Orozco E, Pérez Bartutis GS, Mesa-Pedroso I, Bueno-Alemani N, Infante-Aguilar E, Rodríguez Reinoso JL, Melo-Suarez G, Limonta-Fernández M, Ayala-Ávila M, Muzio-González VL; ISMAELILLO Clinical Trial Group. Cinza-Estévez Z, et al. Among authors: ayala avila m. EClinicalMedicine. 2023 Aug 18;63:102160. doi: 10.1016/j.eclinm.2023.102160. eCollection 2023 Sep. EClinicalMedicine. 2023. PMID: 37649806 Free PMC article.
Active immunization with a structurally aggregated PD-L1 antigen breaks T and B immune tolerance in non-human primates and exhibits in vivo anti-tumoral effects in immunocompetent mouse tumor models.
Morera-Díaz Y, Canaán-Haden C, Sánchez-Ramírez J, Bequet-Romero M, Gonzalez-Moya I, Martínez R, Falcón V, Palenzuela D, Ayala-Ávila M, Gavilondo JV. Morera-Díaz Y, et al. Among authors: ayala avila m. Cancer Lett. 2023 May 1;561:216156. doi: 10.1016/j.canlet.2023.216156. Epub 2023 Apr 3. Cancer Lett. 2023. PMID: 37019172
20 results